Reviewing Century Therapeutics (NASDAQ:IPSC) & Hikma Pharmaceuticals (OTCMKTS:HKMPF)

Hikma Pharmaceuticals (OTCMKTS:HKMPF) and Century Therapeutics (NASDAQ:IPSC) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Insider and Institutional Ownership

50.2% of Century Therapeutics shares are owned by institutional investors. 4.4% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Hikma Pharmaceuticals has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500.

Earnings and Valuation

This table compares Hikma Pharmaceuticals and Century Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	$3.13 billion	1.54	$359.00 million	N/A	N/A
Century Therapeutics	$6.59 million	27.32	-$126.57 million	($0.32)	-6.44

Hikma Pharmaceuticals has higher revenue and earnings than Century Therapeutics.

Analyst Recommendations

This is a breakdown of recent ratings for Hikma Pharmaceuticals and Century Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	1	0	1	0	2.00
Century Therapeutics	1	1	4	1	2.71

Century Therapeutics has a consensus target price of $3.80, indicating a potential upside of 84.47%. Given Century Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Century Therapeutics is more favorable than Hikma Pharmaceuticals.

Profitability

This table compares Hikma Pharmaceuticals and Century Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	N/A	N/A	N/A
Century Therapeutics	N/A	-10.01%	-6.58%

Summary

Century Therapeutics beats Hikma Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

About Century Therapeutics

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.